RecruitingPhase 2NCT05732961

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Studying Myeloproliferative neoplasm

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
Rami Komrokji, MD
Moffitt Cancer Center
Intervention
Luspatercept(drug)
Enrollment
70 target
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (1)

Collaborators

Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05732961 on ClinicalTrials.gov

Other trials for Myeloproliferative neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Myeloproliferative neoplasm

← Back to all trials